Christopoulos, P., , Bozorgmehr, F., Elsayed, M., Kirchner, M., Ristau, J., … Thomas, M. (2018). EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ NSCLC. International Journal of Cancer. https://doi.org/10.1002/ijc.31275 (Original work published 2018)